磁共振兼容头部固定装置的研制及中枢神经系统肿瘤磁共振引导放疗的初步经验
研究研制了Unity脑肿瘤固定装置(UBID),并在1.5T磁共振直线加速器(MR-LINAC)上评估其体位重复性及临床可行性;2022年6月至10月回顾性分析20例中枢神经系统肿瘤放疗患者,其中15例使用UBID。UBID的MR质量因子满足Elekta标准,分次间和分次内中位误差小,作者结论为UBID在1.5T MR-LINAC治疗中枢神经系统肿瘤中临床可行。
要点
- UBID的MR质量因子满足Elekta标准。
- 分次间中位位移左右、前后、头脚方向分别为2.98、2.35、1.40 mm。
- 分次内中位位移左右、前后、头脚方向分别为0.05、0.03、0.06 mm。
核心结论
- 可重复且固定的UBID在中枢神经系统肿瘤患者接受1.5T MR-LINAC放疗中临床可行。
- 基于初步经验,作者制定了1.5T MR-LINAC治疗中枢神经系统肿瘤的工作流程。
研究设计与样本
- 定量分析:将仅放置MR模体的图像与放置UBID于MR模体旁的图像进行比较。
- 回顾性分析2022年6月至10月接受1.5T MR-LINAC放疗的中枢神经系统肿瘤患者20例,其中15例使用UBID、5例未使用。
- 采用前10次分次的分次间和分次内中位误差评估UBID的体位重复性。
主要发现
- UBID的每个MR质量因子均满足Elekta提出的标准。
- 分次间误差中位位移:左右方向2.98 mm、前后方向2.35 mm、头脚方向1.40 mm。
- 分次内误差中位位移:左右方向0.05 mm、前后方向0.03 mm、头脚方向0.06 mm。
- 分次间和分次内俯仰、翻滚、偏航的中位旋转均为0.00°。
- 1例视神经鞘脑膜瘤患者在照射期间接受运动监测;2例分别于首次治疗当日和紧邻第21次分次前通过1.5T MR-LINAC的MRI观察到瘤腔和残留病灶变化,因此进行了离线/在线自适应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to develop and investigate positional reproducibility using a fixation device (Unity Brain tumor Immobilization Device [UBID]) in patients with brain tumor undergoing magnetic resonance (MR)-guided radiation therapy (RT) with a 1.5 Tesla (T) MR-linear accelerator (MR-LINAC) to evaluate its feasibility in clinical practice and report representative cases of patients with central nervous system (CNS) tumor. MATERIALS AND METHODS: Quantitative analysis was performed by comparing images obtained by placing only the MR phantom on the couch with those obtained by placing UBID next to the MR phantom. Twenty patients who underwent RT for CNS tumors using 1.5T MR-LINAC between June and October 2022 were retrospectively analyzed. Among them, 5 did not use UBID, whereas 15 used UBID. The positional reproducibility of UBID was evaluated using the median interfractional and intrafractional errors in the first 10 fractions. RESULTS: Each MR quality factor of the MR phantom with UBID satisfied the criteria presented by Elekta. Median values of median shifts in the mediolateral, anteroposterior, and craniocaudal axes for interfractional errors were 2.98, 2.35, and 1.40 mm, respectively. For intrafractional errors, the median values were 0.05, 0.03, and 0.06 mm, respectively. The median values of the median rotations in pitch, roll, and yaw for both interfractional and intrafractional rotations were 0.00°. One patient diagnosed with an optic nerve sheath meningioma received RT with motion monitoring during irradiation. In 2 patients, changes in the tumor cavity and residual lesions were observed in the MRI obtained using 1.5T MR-LINAC on the day of the first treatment and immediately before the 21st fraction, respectively; therefore, offline/online adaptation was performed. CONCLUSIONS: The reproducible and immobile UBID is clinically feasible in patients with CNS tumors receiving RT with 1.5T MR-LINAC. Based on our initial experience, we developed a workflow for 1.5T MR-LINAC treatment of CNS tumors.
引用
- Lee J, Shin NY, Lee SJ, et al. Development of Magnetic Resonance-Compatible Head Immobilization Device and Initial Experience of Magnetic Resonance-Guided Radiation Therapy for Central Nervous System Tumors. Pract Radiat Oncol. 2024. PMID: 38697347. doi:10.1016/j.prro.2024.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。